Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: Analysis of clinical features and outcomes from the Asia Lymphoma study group

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Kim, Seok Jin ^a   Jung, Hyun Ae ^a   Chuang, Shih Sung ^b   Hong, Huangming ^c   Guo, Cheng Cheng ^c   Cao, Junning ^d   Hong, Xiao Nan ^d   Suzuki, Ritsuro ^e   Kang, Hye Jin ^f   Won, Jong Ho ^g   Chng, Wee Joo ^h   Kwong, Yok Lam ⁱ   Suh, Cheolwon ^j   Song, Yu Qin ^k   Zhu, Jun ^k   Tay, Kevin ^l   Lim, Soon Thye ^l   Suzumiya, Junji ^m   Lin, Tong Yu ^c   Kim, Won Seog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c SUN YAT SEN UNIVERSITY   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Korea Cancer Center Hospital   (South Korea)

^g Soonchunhyang University College of Medicine   (South Korea)

^h NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

ⁱ QUEEN MARY HOSPITAL   (Hong Kong)

^j University of Ulsan College of Medicine   (South Korea)

^k PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^l DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^m SHIMANE UNIVERSITY   (Japan)

more..

Author keywords

Extranodal NK T cell lymphoma; Gastrointestinal tract; Prognosis

Indexed keywords

ASPARAGINASE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMOSURGERY; CLINICAL FEATURE; DIGESTIVE SYSTEM CANCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HUMAN; ILEUM; INTESTINE PERFORATION; JEJUNUM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NK T CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; SYSTEMIC THERAPY;

ADOLESCENT; ADULT; AGED; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887512919     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-86     Document Type: Article

References (12)

1. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Kim SJ, Kim WS, Int J Hematol 2010 92 690 696 10.1007/s12185-010-0720-8 21086194
2. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS, Ann Oncol 2012 23 2703 2707 10.1093/annonc/mds096 22547542
3. Primary CD56 positive lymphomas of the gastrointestinal tract. Chim CS, Au WY, Shek TW, Ho J, Choy C, Ma SK, Tung HM, Liang R, Kwong YL, Cancer 2001 91 525 533 10.1002/1097-0142(20010201)91:3<525::AID-CNCR1030>3.0.CO;2-U 11169934 (Pubitemid 32105697)
4. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma study group. D'Amore F, Brincker H, Gronbaek K, Thorling K, Pedersen M, Jensen MK, Andersen E, Pedersen NT, Mortensen LS, J Clin Oncol 1994 12 1673 1684 8040680 (Pubitemid 24245004)
5. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR, Cancer 1998 83 806 812 9708949
6. Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). Kim SJ, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, Kim WS, BMC Cancer 2011 11 321 10.1186/1471-2407-11-321 21798075
7. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS, Blood 2011 117 1958 1965 10.1182/blood-2010-06-288480 21148334
8. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS, J Clin Oncol 2006 24 612 618 10.1200/JCO.2005.04. 1384 16380410 (Pubitemid 46630424)
9. A note on quantifying follow-up in studies of failure time. Schemper M, Smith TL, Control Clin Trials 1996 17 343 346 10.1016/0197-2456(96)00075-X 8889347 (Pubitemid 26342716)
10. Epidemiologic overview of malignant lymphoma. Huh J, Korean J Hematol 2012 47 92 104 10.5045/kjh.2012.47.2.92 22783355
11. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R, J Clin Oncol 2011 29 4410 4416 10.1200/JCO.2011.35.6287 21990393
12. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS, Blood 2012 120 2973 2980 10.1182/blood-2012-05-431460 22919026